FindTrial
Sign In

AMG 386 Placebo

DRUG7 trials

Sponsors

Amgen

Conditions

CancerCarcinomaColon CancerColorectal CancerFallopian Tube CancerGastrointestinal CancerLocally Recurrent and Metastatic Breast CancerMetastases

Phase 1

Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer
CompletedNCT01666977
AmgenNon Small Cell Lung Cancer
Start: 2012-08-31End: 2015-11-30Updated: 2016-06-03

Phase 2

Phase 2 AMG 386 in Comb. Paclitaxel for Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer
CompletedNCT00479817
AmgenFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Start: 2007-07-05End: 2019-12-09Updated: 2019-12-18
Phase 2 Study of AMG 386 Plus Paclitaxel With or Without Bevacizumab as First Line Therapy in Her2-Negative Breast Cancer Patients
CompletedNCT00511459
AmgenLocally Recurrent and Metastatic Breast Cancer
Start: 2007-07-31End: 2014-05-31Updated: 2015-10-29
Phase 2 Study of AMG 386 (20060439) in Combination With Cisplatin & Capecitabine in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma
CompletedNCT00583674
AmgenGastrointestinal Cancer
Start: 2007-12-31End: 2012-06-30Updated: 2014-05-07
A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
CompletedNCT00752570
AmgenCancer, Carcinoma, Colon Cancer +7
Start: 2008-11-30End: 2012-06-30Updated: 2015-09-02

Phase 3

TRINOVA-1: A Study of AMG 386 or Placebo, in Combination With Weekly Paclitaxel Chemotherapy, as Treatment for Ovarian Cancer, Primary Peritoneal Cancer and Fallopian Tube Cancer
CompletedNCT01204749
AmgenFallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cancer
Start: 2010-11-30End: 2016-12-31Updated: 2016-12-15
TRINOVA-3: A Study of AMG 386 or AMG 386 Placebo in Combination With Paclitaxel and Carboplatin to Treat Ovarian Cancer
TerminatedNCT01493505
AmgenFallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
Start: 2012-01-31End: 2016-12-31Updated: 2017-02-23

Related Papers

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
2019-05-0767 citations
Health-related quality of life in women with recurrent ovarian cancer receiving paclitaxel plus trebananib or placebo (TRINOVA-1).
2016-03-306 citations
Impact of trebananib plus weekly paclitaxel on overall survival (OS) in patients (pts) with recurrent ovarian cancer and ascites: Results from the phase III TRINOVA-1 study.
Journal of Clinical Oncology2015-05-2015 citations
Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase 2 randomized study
The Breast2015-03-0549 citations
Anti-angiopoietin therapy with trebananib for recurrent ovarian cancer (TRINOVA-1): a randomised, multicentre, double-blind, placebo-controlled phase 3 trial.
2014-06-17211 citations
Expression of angiopoietin (Ang) pathway markers and their relationship to progression-free survival (PFS) in TRINOVA-1.
Journal of Clinical Oncology2014-05-20
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
2012-10-2852 citations